애프터마켓
로그인 회원가입
PODD
PODD
Insulet Corp
7월 27일 4:00 PM ET (한국 7/28 05:00)
$165.00
+1.74 ▲ +1.07%
🌙 7월 27일 4:15 PM ET (한국 7/28 05:15)
$165.00
+0.00 +0.00%

인슐렛(PODD) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$11.4B
미드캡
P/E
38.4
적정 수준
배당수익률
없음
52주 위치
12%
저점 +19% · 고점 -54%
애널리스트
적극 매수
B+
Fundamental health
vs. Medical Devices
수익성 ⓘ
Top 20%
성장 ⓘ
Top 6%
밸류에이션 ⓘ
Top 33%
재무 안정 ⓘ
Top 44%
💰 Is this stock pricier than usual right now? ⓘ
Compared to this company's own recent 5년 (not other companies).
💎 Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 37원. Over the past 5년, it usually traded around 88원. One of the cheapest stretches of the past 5년.
Pricy doesn't mean bad — it means expectations are already baked in.
Index ⓘ S&P 500P/E ⓘ 38.4EPS (ttm) ⓘ 4.3Insider Own ⓘ 0.43%Shs Outstand ⓘ 69.3MPerf Week ⓘ -1.42%
Market Cap ⓘ 11.43BForward P/E ⓘ 20.49EPS next Y ⓘ 24.34%Insider Trans ⓘ 4.25%Shs Float ⓘ 69.0MPerf Month ⓘ 7.27%
Enterprise Value ⓘ 11.90BPEG ⓘ 0.77EPS next Q ⓘ 1.45Inst Own ⓘ 103.81%Short Float ⓘ 6.74%Perf Quarter ⓘ -12.96%
Income ⓘ 0.30BP/S ⓘ 3.94EPS this Y ⓘ 30.34%Inst Trans ⓘ -1.41%Short Ratio ⓘ 2.88Perf Half Y ⓘ -39.25%
Sales ⓘ 2.90BP/B ⓘ 8.77EPS next 5Y ⓘ 26.68%ROA ⓘ 9.31%Short Interest ⓘ 4.65MPerf YTD ⓘ -41.95%
Book/sh ⓘ 18.81P/C ⓘ 23.79EPS past 3/5Y ⓘ 275.33% 102.14%ROE ⓘ 23%52W High ⓘ -53.51% ($354.88)Perf Year ⓘ -43.15%
Cash/sh ⓘ 6.94P/FCF ⓘ 27.49Sales past 3/5Y ⓘ 27.54% 24.53%ROIC ⓘ 13.57%52W Low ⓘ 18.88% ($138.79)Perf 3Y ⓘ -40.56%
Dividend Est. ⓘ -EV/EBITDA ⓘ 19.01EPS Y/Y TTM ⓘ -24.86%Gross Margin ⓘ 71.64%Volatility(W/M) ⓘ 3.33% 3.75%Perf 5Y ⓘ -38.17%
Dividend TTM ⓘ -EV/Sales ⓘ 4.1Sales Y/Y TTM ⓘ 31.93%Oper. Margin ⓘ 17.47%ATR (14) ⓘ 6.27Perf 10Y ⓘ 372.37%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 1.78EPS Q/Q ⓘ 158.51%Profit Margin ⓘ 10.44%RSI (14) ⓘ 56.72Recom ⓘ 1.48
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 2.45Sales Q/Q ⓘ 33.87%SMA20 ⓘ 2.54% ($160.91)Beta ⓘ 1.09Target Price ⓘ $234.95
Payout ⓘ -Debt/Eq ⓘ 0.73Earnings ⓘ 2026/8/5SMA50 ⓘ 7.14% ($154)Rel Volume ⓘ 0.69Prev Close ⓘ $163.26
Employees ⓘ 5400LT Debt/Eq ⓘ 0.71EPS/Sales Surpr. ⓘ 18.46% 4.36%SMA200 ⓘ -29.83% ($235.14)Avg Volume(3M) ⓘ 1.61MPrice ⓘ $165
IPO ⓘ 2007/5/15Option/Short ⓘ Yes/YesTrades ⓘ 18982Volume ⓘ 1,115,212Change ⓘ 1.07%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $762M (YoY +34%) · 순이익 $91M (YoY +157%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Insulet Corp (PODD) Investment Analysis

What kind of company is Insulet Corp?

인슐렛(PODD) 성장주
Healthcare · Medical Devices
#878 by Market Cap — Mid-Cap

This US medical device company develops and sells tubeless, disposable insulin pumps (Omnipod), a diabetes management device. Its growth is driven by recurring revenue from consumable pumps and the expanding diabetic population.

Learn more about Insulet Corp →
Market Cap
$11.4B
Approx. KRW 15.7 trillion
⚖️ 4% of Samsung Electronics
Market Cap Rank878
Employees5,400people
IPO2007/05/15
Current Price$165.00 ≈ 226,050원
📌 S&P 500 · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release D-9
8월 5일 (수) · 장 시작 전
예상 EPS $1.45
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 6일 (수) · 장 시작 전 EPS +18.5% 매출 +4.4%
🔔 Earnings release 2026년 2월 18일 (수) · 장 시작 전

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
17.5%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Devices Median -23.9% · Top 5%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
10.4%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Devices Median -34.5% · Top 14%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
71.6%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Devices Median 54.4% · Top 21%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
23.0%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 대형주 Median 11.9% · Top 25%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
9.3%
✓ 양호
My positionMid-range
Low range Average High range
Healthcare 대형주 Median 5.1% · Top 29%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
13.6%
✓ 양호
My positionMid-range
Low range Average High range
Healthcare 대형주 Median 7.4% · Top 29%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.73
✓ Average
My positionMid-range
Low range Average High range
Medical Devices Median 0.39
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
2.45
✓ 양호
My positionMid-range
Low range Average High range
Medical Devices Median 2.91
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.78
✓ 양호
My positionMid-range
Low range Average High range
Medical Devices Median 2.09
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$234.95
현재가 대비 +42.4%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
20.49배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
0.77
저평가
💡 PEG < 1 — 성장 대비 저렴
내년 EPS 예상 성장률
+24.3%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+26.7%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+12.6%
평균 서프라이즈
2026.05.06
상회
실적 $1.42 · 예상 $1.19 +19.3%
2026.02.18
상회
실적 $1.55 · 예상 $1.46 +6.0%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+30.3%
우수
My positionTop 25%
Low range Average High range
성장주 대형주 Median 15.4% · Top 20%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+24.3%
우수
My positionTop 25%
Low range Average High range
성장주 대형주 Median 13.1% · Top 13%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+26.7%
우수
My positionTop 5%
Low range Average High range
성장주 대형주 Median 14.9% · Top tier
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+275.3%
우수
My positionTop 5%
Low range Average High range
성장주 대형주 Median 9.2% · Top tier
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+102.1%
우수
My positionTop 5%
Low range Average High range
성장주 대형주 Median 13.8% · Top tier
Past 5-Year Revenue
How much revenue grew over the past 5 years
+24.5%
우수
My positionTop 5%
Low range Average High range
성장주 대형주 Median 10.3% · Top tier
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+33.9%
우수
My positionTop 25%
Low range Average High range
성장주 대형주 Median 11.2% · Top 8%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -107%p below the market
PODD -38.2% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-106.5%p
Significantly behind the market
vs Health Care (XLV)
-62.7%p
Significantly behind the sector average
1-year basis
vs S&P 500
-59.2%p
Significantly behind the market
vs Health Care (XLV)
-62.9%p
Significantly behind the sector average
Rank among peers
5-year return Bottom 24% Based on 13 peers
1-year return Lowest among peers Based on 14 peers
Current position within 52-week range
Low (-18.9%p) High (-53.5%p)
Current price is 18.9% above the 52-week low and 53.5% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-46.2%
Annualized volatility
47.1%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 137-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-27
Uptrend zone

Current price $165.00 above the midline ($160.92). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢
Current diagnosis · 2026-07-27
Bullish momentum holding

MACD 2.174 > Signal 2.035 in positive zone + Hist positive (+0.139). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 56.7 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 71.6.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
Pricey on Vs. Assets, In line with peers on Vs. Earnings·Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Mid-range
🏢 Vs. Assets Pricey
🧾 Vs. Sales Mid-range
💧 Vs. Cash Flow Mid-range
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
38.40x
✓ Fair
My positionMid-range
Low range Average High range
Medical Devices median 30.60x · Around the industry average
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
20.49x
✓ Fair
My positionMid-range
Low range Average High range
Medical Devices median 17.57x · Around the industry average
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
8.77x
✓ Pricey
My positionBottom 25%
Low range Average High range
Medical Devices median 2.58x · Bottom 14% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
3.94x
✓ Fair
My positionMid-range
Low range Average High range
Medical Devices median 2.64x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
19.01x
✓ Fair
My positionMid-range
Low range Average High range
Medical Devices median 14.42x · Around the industry average
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
27.49x
✓ Fair
My positionMid-range
Low range Average High range
Medical Devices median 21.45x · Around the industry average
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$234.95 vs. current price +42.4%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Medical Devices

Who owns it?

Ownership flow shows some pressure
Insider modest net buying +4.3% · Institutional net selling -1.4% · Short interest moderate 6.7% · Short interest up +2.7pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
+4.3%
Insiders net buying
🏦 Institutions (funds & investors)
-1.4%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 103.8%
Institution-led, stable structure
Healthcare 대형주 Median 91.9%
🧑‍💼 Insiders 0.4%
Low, common among large-caps
Healthcare 대형주 Median 0.8%
👤 Retail investors (estimated) 0.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
6.7%
Moderate
Healthcare 대형주 Median 3.6%
Past 90 days 📈 +2.7%p increase
Short interest days to cover
2.9 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 69.3M주
Float (tradable shares) 69.0M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding PODD

ETFs with the highest weightings · 10 total shown
LGHT
LGHT
Langar Global HealthTech ETF
5.01%
$2M
EKG
EKG
First Trust Nasdaq Lux Digital Health Solutions ETF
3.77%
$4M
HEAL
HEAL
Global X HealthTech ETF
3.50%
$28M
NLSI
NLSI
NEOS Long/Short Equity Income ETF
3.28%
$3M
BCSM
BCSM
Baron SMID Cap ETF
2.60%
$32M
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
PODD PODD This Stock
$11.4B38.4 ▼8.8 ▼23% ▲- +1.1%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
인슐렛(PODD) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
PODD(인슐렛)는 몸에 붙이는 일회용 인슐린 펌프를 판매하는 미국 의료기기 기업으로, 펌프 신규 가입자와 반복 소모품 매출, 당뇨 인구 증가와 2형 당뇨·해외 확대, 경쟁이 실적과 주가 전망의 핵심으로 꼽히는 종목입니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 인슐렛(PODD)?

인슐렛(PODD) belongs to the Healthcare sector and operates in the Medical Devices industry.

What is the market cap of PODD?

The market cap of PODD is approximately $11.4B, ranking 878 within its sector.

What is the P/E ratio of PODD?

PODD has a P/E ratio of approximately 38.4x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for PODD?

PODD has recorded a 52-week high of $354.88 and a low of $138.79.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.